Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ariad Pharmaceuticals Inc Announces 12-Month Data From Pivotal PACE Trial Of Ponatinib In Heavily Pretreated Patients


Tuesday, 11 Dec 2012 08:05am EST 

Ariad Pharmaceuticals Inc announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, investigational BCR-ABL inhibitor, in heavily pretreated patients with advanced forms of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that 57% of accelerated-phase CML patients in the trial, including 50% of patients with the T315I mutation, achieved hematologic response (MaHR), the primary end-point for patients with advanced disease in the trial. 

Company Quote

5.77
0.01 +0.17%
4:00pm EDT